Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 6/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL989622 | 0.85 | — | — | |
| SCHEMBL3628762 | 0.85 | — | — | |
| SCHEMBL6922015 | 0.80 | TLR4 (0.47) | TLR4CYP1A2MAPK1HIF1AKDM4E | |
| SCHEMBL25061 | 0.77 | MAPK1 (0.47) | TLR4CYP1A2MAPK1HIF1AKDM4E | |
| SCHEMBL374935 | 0.77 | MAPK1 (0.47) | TLR4CYP1A2MAPK1HIF1AKDM4E | |
| SCHEMBL31276435 | 0.77 | MAPK1 (0.47) | TLR4CYP1A2MAPK1HIF1AKDM4E | |
| SCHEMBL3171 | 0.76 | MAPK1 (0.54) | CYP1A2MAPK1HIF1AKDM4EHSD17B10 | |
| SCHEMBL20303983 | 0.76 | MAPK1 (0.54) | CYP1A2MAPK1HIF1AKDM4EHSD17B10 | |
| SCHEMBL31198171 | 0.76 | MAPK1 (0.46) | TLR4CYP1A2MAPK1HIF1AKDM4E | |
| SCHEMBL7305358 | 0.76 | MAPK1 (0.54) | CYP1A2MAPK1HIF1AKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9475769-B2 | Zinc halide mediated cyclization process leading to tricyclic indoles | GE HEALTHCARE LIMITED (GB) | 2016-10-25 | — | — | US | disclosed |
| US-20150336891-A1 | Zinc Halide Mediated Cyclization Process Leading to Tricyclic Indoles | GE HEALTHCARE LIMITED (GB) | 2015-11-26 | — | — | US | disclosed |
| EP-2925723-A1 | ZINC HALIDE MEDIATED CYCLIZATION PROCESS LEADING TO TRICYCLIC INDOLES | GE Healthcare Limited (GB) | 2015-10-07 | — | — | EP | disclosed |
| WO-2014083163-A1 | ZINC HALIDE MEDIATED CYCLIZATION PROCESS LEADING TO TRICYCLIC INDOLES | GE HEALTHCARE LIMITED (GB) | 2014-06-05 | — | — | WO | disclosed |
| US-7109231-B2 | Cyclohept[b]indole derivatives | ELI LILLY AND COMPANY (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1438290-B1 | CYCLOHEPT B!INDOLE DERIVATIVES AS SPLA2 INHIBITORS | LILLY CO ELI (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20040198801-A1 | Cyclohept'b!indole derivatives as spla2 inhibitors | KINNICK MICHAEL DEAN (US) | 2004-10-07 | — | — | US | disclosed |
| EP-1438290-A1 | CYCLOHEPT B!INDOLE DERIVATIVES AS SPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2004-07-21 | — | — | EP | disclosed |
| WO-2003016277-A1 | CYCLOHEPT`B!INDOLE DERIVATIVES AS SPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336891-A1 | Zinc Halide Mediated Cyclization Process Leading to Tricyclic Indoles | IDO1, IDO2, TPH2 | TLR4 4490/4885CYP1A2 192/4885MAPK1 4475/4885 |
| US-20040198801-A1 | Cyclohept'b!indole derivatives as spla2 inhibitors | SPTSSB, CPT1A, TPH2 | TLR4 401/4885CYP1A2 507/4885MAPK1 4341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.